We are dedicated to improving the range of products available in Europe to treat urological conditions.
The prevalence of many urological conditions is increasing, largely as a result of the ageing population, and many of these represent major, unmet clinical needs.
Our mission is to be recognised as the leading urology and urogynaecology focused specialty pharmaceutical business in Europe, marketing products directly in the leading EU markets and through expert partners in other regions and countries.
The acquisition of Contura in 2013 is aligned to our strategy to focus in urology and urogynaecology and to expand our commercial geographical presence.
Speciality European Pharma has its own commercial operations in the large European markets – the UK, Germany, France, Italy and the Nordic region.
SEP markets its products in other regions and territories through relationships with expert partners.